Monday, April 11, 2011
StemCells Inc., of Palo Alto, Calif., discontinued a Phase Ib trial of HuCNS-SCA human neuronal stem cells in neuronal ceroid lipofuscinosis (NCL) due to lack of patient accrual. Phase I safety studies were completed in 2009 in six patients with advanced NCL. The Phase Ib trial was to evaluate the therapy in six early stage patients. However, no eligible patients have been found after six months of searching.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.